Revenue Performance - Aspira reported total product revenues of $2.3 million for Q3 2025, remaining flat compared to Q3 2024, with a 7.0% year-over-year increase in average unit price per test[1][2] - The company generated approximately $7.0 million in revenue for the nine months ending September 30, 2025, with a 9.3% increase in average unit price, offset by a 6.4% decrease in the number of tests sold[6] - Total revenue for Q3 2025 was $2,305,000, a 2.1% increase from $2,257,000 in Q3 2024[16] Profitability and Expenses - Gross profit increased to approximately $4.5 million for the nine months ended September 30, 2025, representing a 12.2% increase, with gross margins improving to 64.1% from 58.4% year-over-year[6] - Operating expenses in Q3 2025 totaled $2,962,000, down from $5,099,000 in Q3 2024, indicating a significant reduction[16] - Total operating expenses decreased to $11.1 million for the nine months ended September 30, 2025, a 34.0% reduction from $16.8 million in the same period in 2024[6] - Cash used in operations was $5.0 million for the nine months ended September 30, 2025, representing a 54.5% reduction compared to $11.1 million in the same period in 2024[6] - Net loss for Q3 2025 was $4,892,000, compared to a net loss of $3,547,000 in Q3 2024, showing an increase in losses[16] - Net loss per share for Q3 2025 was $0.13, compared to $0.23 in Q3 2024[16] - Research and development expenses decreased to $739,000 in Q3 2025 from $908,000 in Q3 2024[16] - Sales and marketing expenses significantly decreased to $683,000 in Q3 2025 from $2,143,000 in Q3 2024[16] - General and administrative expenses were $1,540,000 in Q3 2025, down from $2,048,000 in Q3 2024[16] Assets and Liabilities - Aspira's current liabilities decreased to $4.2 million as of September 30, 2025, a 23.2% reduction from $5.5 million reported on December 31, 2024[7] - Total assets increased to $7.3 million as of September 30, 2025, compared to $5.5 million as of December 31, 2024[15] Sales Performance - The company achieved a 167% increase in sales per full-time equivalent salesperson in Q3 2025 compared to Q3 2024, driven by a focus on large healthcare systems[6] Strategic Focus - Aspira is emphasizing profitable revenue growth over specimen volume, with a compensation shift to incentivize this change starting in Q3 2025[3][4] - The company is maintaining strong momentum in research and development, particularly with the ENDOinform™ test, expecting to share updates as it approaches commercial readiness[8] Cost of Revenue - Total cost of revenue for Q3 2025 was $922,000, compared to $902,000 in Q3 2024, showing a slight increase[16]
Aspira Women’s Health (AWH) - 2025 Q3 - Quarterly Results